On September 9, 2026, Serina Therapeutics announced that the Independent Safety Monitoring Committee completed its blinded review of Cohort 1 of the Phase 1b registrational study for SER-252 in advanced Parkinson's disease and recommended advancing to Cohort 2. The cohort evaluated the lowest dose level in the single-ascending-dose portion, involving eight patients randomized 3:1 to receive SER-252 or placebo. Blinded observations indicated a pharmacokinetic profile consistent with sustained apomorphine exposure and sustained periods of improvement in motor function on exploratory clinical measures. The company expects to report topline data from the single-ascending-dose portion in the first half of 2027. Serina Therapeutics is a clinical-stage biotechnology company developing proprietary drug optimization technology for Parkinson's disease.
